Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- RaQualia, Asahi Kasei Pharma Conclude Joint Drug Discovery Research
April 14, 2014
- 10% of Valsartan Franchise Prescriptions Switched to Other ARBs, Azilva, Micamlo Top Lists
April 11, 2014
- Chugai Files NDA for Vemurafenib for Melanoma with BRAF Mutation, Roche Diagnostics Files for Companion Diagnostics
April 11, 2014
- 17 Patients Who Took Xeplion Have Died since November Launch
April 10, 2014
- Kyowa Kirin Completes Biopharmaceutical API Manufacturing Facility, Eying Start of Operations from 2016
April 10, 2014
- Announcement: 7th Annual Marketing Excellence Japan 2014 – Westin Tokyo, May 13 – 14
April 9, 2014
- US Jury Orders Takeda to Pay US$6 Billion in Punitive Damages
April 9, 2014
- GSK Voluntarily Recalls Paxil in Japan, No Reports of Adverse Reactions
April 9, 2014
- ViiV, Shionogi to Copromote Anti-HIV Drug Tivicay at 100 Major Facilities
April 9, 2014
- DSP Subsidiary Sunovion Launches Antiepileptic Drug Aptiom in US
April 9, 2014
- Livalo Lawsuit: Does Use of “PITAVA” by Generic Makers Infringe Kowa Trademark?
April 9, 2014
- Ethical Drug Sales Up 3.0% in February Due to Flu Epidemic: Crecon Report
April 9, 2014
- Bayer Yakuhin Sales Up 16.5% Driven by New Product Growth
April 9, 2014
- Oncolys, BMS End Collaboration for Anti-HIV Drug Development
April 9, 2014
- Santen Licenses Tafluprost Marketing Rights in US to Oak Pharmaceuticals
April 9, 2014
- Sun Deal Not Meant to Sever Ties with Ranbaxy: Daiichi Sankyo Pres.
April 8, 2014
- Daiichi Sankyo’s Governance over Ranbaxy Shaky to the End
April 8, 2014
- Novartis Gives Update on SIGN Probe, Personnel Change to JPMA
April 8, 2014
- Why Did Sanofi Decide to Begin Independent Marketing? Future Relationship with Nichi-Iko Remains in Doubt
April 8, 2014
- Japan Generic Market Put at 780 Billion Yen in 2016, Biosimilars 26.4 Billion Yen: Fuji Keizai
April 8, 2014
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…